Inovio Pharmaceuticals (INO) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic focus and regulatory progress

• Lead candidate INO-3107 for RRP is under FDA review with a PDUFA date set for October 30th, supported by orphan drug and breakthrough therapy designations in the US and orphan status in the EU.

• Late-stage FDA review is ongoing, with label negotiations anticipated in September and all scheduled inspections completed.

• Commercial preparations for INO-3107 are ramping up, aiming to establish it as the new standard of care for RRP.

• Cash runway extends into late Q1 next year, supporting potential product launch.

Clinical data and differentiation

• INO-3107 demonstrated a 50%-100% reduction in surgeries for 72% of patients in year one, improving to 86% in year two.

• 28% of patients required no surgery in the first year post-treatment, increasing to 50% in the second year.

• Unlike existing therapies, INO-3107 does not require minimal residual disease surgeries during treatment and is unaffected by pre-existing neutralizing antibodies or immunosuppressive microenvironments.

• Supported by the RRP Foundation, highlighting strong patient advocacy and need for innovative therapies.

Commercial and pipeline strategy

• Plans include leveraging field teams, contract sales, targeted marketing, and a patient hub to drive adoption and access.

• Pipeline includes late-stage HPV and oncology candidates, with VGX-3100 showing positive phase III results in China and potential for milestone and royalty payments.

• Partnership with Akeso and Dana-Farber Cancer Institute to evaluate INO-5412 in glioblastoma as part of the INSIGhT trial.